Arginase inhibitor and pharmaceutical composition comprising same

Novel pyrrolidine-based arginase inhibitors address the challenge of tumor immune evasion by restoring arginine levels, enhancing cytotoxic T-cell activity and offering a treatment or prevention strategy for cancers.

WO2026117030A1PCT designated stage Publication Date: 2026-06-04DAEWOONG PHARM CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2025/019937
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-27
Filing Date
2025-11-27
Publication Date
2026-06-04

AI Technical Summary

Technical Problem

Current cancer treatments face challenges in effectively inhibiting arginase activity in the tumor microenvironment, which allows tumor cells to evade immune destruction, necessitating the development of novel arginase inhibitors to restore arginine levels and enhance cytotoxic T-cell activity.

Method used

Development of novel pyrrolidine-based arginase inhibitors with new chemical structures, represented by specific compounds like 6-amino-8-(2-voronoethyl)-2-azaspiro[4.5]decane-6-carboxylic acid and its derivatives, which inhibit arginase and restore arginine levels, promoting tumor-killing activity of cytotoxic T-cells.

Benefits of technology

The novel arginase inhibitors effectively restore arginine levels in the tumor microenvironment, enhancing the tumor-killing activity of cytotoxic T-cells and providing a potential treatment or prevention strategy for various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2025019937_04062026_PF_FP_ABST
    Figure KR2025019937_04062026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a compound represented by the following chemical formula 1, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising same can be advantageously used for the prevention or treatment of cancer or tumors. [Chemical Formula 1] In chemical formula 1, X1 and X2 are as defined in the specification.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Compositions and methods for inhibiting arginase activity

    US20170121352A1

  • Arginase Inhibitors and Their Therapeutic Applications

    US20170319536A1

  • Arginase inhibitors and methods of use

    WO2019177873A1

  • Arginase inhibitors and methods of use

    WO2019245890A1

  • Arginase inhibitors and methods of use

    WO2021141751A1